Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
NCT01730586Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Aug 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in colorectal adenocarcinoma and small bowel adenocarcinoma (SBA), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Rate at 21 days. Started Nov 2012; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
colorectal adenocarcinomasmall bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT01730586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730586.